Differential involvement of mitochondrial dysfunction, cytochrome P450 activity, and active transport in the toxicity of structurally related NSAIDs

Toxicology in Vitro

Volumn 26, Issue 2, 2012, Pages 197-205

  van Leeuwen, Jolanda S ^a   Ünlü, Betül ^a   Vermeulen, Nico P E ^a   Vos, J Chris ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Cytochrome P450; Multidrug resistance; NSAID; Reactive oxygen species; Yeast

Indexed keywords

ABC TRANSPORTER; CYTOCHROME P450; DICLOFENAC; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PDR5 PROTEIN; REACTIVE OXYGEN METABOLITE; SNQ2 PROTEIN; SULINDAC; UNCLASSIFIED DRUG; ZOMIPERAC;

ACTIVE TRANSPORT; AEROBIC METABOLISM; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; ENZYME METABOLISM; MITOCHONDRIAL RESPIRATION; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION; YEAST CELL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; ELECTRON TRANSPORT; GENES, MDR; IBUPROFEN; INDOMETHACIN; KETOPROFEN; KETOROLAC; MITOCHONDRIA; NAPROXEN; REACTIVE OXYGEN SPECIES; SULINDAC; TOLMETIN; YEASTS;

SACCHAROMYCES CEREVISIAE;

EID: 84856437125     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2011.11.013     Document Type: Article

References (50)

1. Agundez J.A., Garcia-Martin E., Martinez C. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?. Expert Opin. Drug Metab. Toxicol. 2009, 5:607-620.
2. Allen C.N., Harpur E.S., Gray T.J., Hirst B.H. Toxic effects of non-steroidal anti-inflammatory drugs in a human intestinal epithelial cell line (HCT-8), as assessed by the MTT and neutral red assays. Toxicol. In Vitro 1991, 5:183-191.
3. Brunell D., Sagher D., Kesaraju S., Brot N., Weissbach H. Studies on the metabolism and biological activity of the epimers of sulindac. Drug Metab. Dispos. 2011, 39:1014-1021.
4. Campos C.B., Degasperi G.R., Pacifico D.S., Alberici L.C., Carreira R.S., Guimaraes F., Castilho R.F., Vercesi A.E. Ibuprofen-induced Walker 256 tumor cell death: cytochrome c release from functional mitochondria and enhancement by calcineurin inhibition. Biochem. Pharmacol. 2004, 68:2197-2206.
5. Chen Q., Doss G.A., Tung E.C., Liu W., Tang Y.S., Braun M.P., Didolkar V., Strauss J.R., Wang R.W., Stearns R.A., Evans D.C., Baillie T.A., Tang W. Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats. Drug Metab. Dispos. 2006, 34:145-151.
6. Daly A.K., Aithal G.P., Leathart J.B., Swainsbury R.A., Dang T.S., Day C.P. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007, 132:272-281.
7. Damsten M.C., van Vugt-Lussenburg B.M., Zeldenthuis T., de Vlieger J.S., Commandeur J.N., Vermeulen N.P. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. Chem. Biol. Interact. 2008, 171:96-107.
8. El-Sheikh A.A., van den Heuvel J.J., Koenderink J.B., Russel F.G. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP)2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J. Pharmacol. Exp. Ther. 2007, 320:229-235.
9. Fosbol E.L., Gislason G.H., Jacobsen S., Folke F., Hansen M.L., Schramm T.K., Sorensen R., Rasmussen J.N., Andersen S.S., Abildstrom S.Z., Traerup J., Poulsen H.E., Rasmussen S., Kober L., Torp-Pedersen C. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin. Pharmacol. Ther. 2009, 85:190-197.
10. Goldring E.S., Grossman L.I., Krupnick D., Cryer D.R., Marmur J. The petite mutation in yeast. Loss of mitochondrial deoxyribonucleic acid during induction of petites with ethidium bromide. J. Mol. Biol. 1970, 52:323-335.
11. Grillo M.P., Ma J., Teffera Y., Waldon D.J. A novel bioactivation pathway for diclofenac initiated by P450 mediated oxidative decarboxylation. Drug Metab. Dispos. 2008, 36:1740-1744.
12. Ho C.H., Piotrowski J., Dixon S.J., Baryshnikova A., Costanzo M., Boone C. Combining functional genomics and chemical biology to identify targets of bioactive compounds. Curr. Opin. Chem. Biol. 2011, 15:66-78.
13. Hoon S., St Onge R.P., Giaever G., Nislow C. Yeast chemical genomics and drug discovery: an update. Trends Pharmacol. Sci. 2008, 29:499-504.
14. Jurima-Romet M., Crawford K., Huang H.S. Comparative cytotoxicity of non-steroidal anti-inflammatory drugs in primary cultures of rat hepatocytes. Toxicol. In Vitro 1994, 8:55-66.
15. Katzmann D.J., Burnett P.E., Golin J., Mahe Y., Moye-Rowley W.S. Transcriptional control of the yeast PDR5 gene by the PDR3 gene-product. Mol. Cell. Biol. 1994, 14:4653-4661.
16. Klebe R.J., Harriss J.V., Sharp Z.D., Douglas M.G. A general method for polyethylene-glycol-induced genetic transformation of bacteria and yeast. Gene 1983, 25:333-341.
17. Kliewer S.A., Goodwin B., Willson T.M. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 2002, 23:687-702.
18. Komuro M., Higuchi T., Hirobe M. Application of chemical cytochrome-P-450 model systems to studies on drug-metabolism. 8. Novel metabolism of carboxylic-acids via oxidative decarboxylation. Bioorg. Med. Chem. 1995, 3:55-65.
19. Kowaltowski A.J., de Souza-Pinto N.C., Castilho R.F., Vercesi A.E. Mitochondria and reactive oxygen species. Free Radic. Biol. Med. 2009, 47:333-343.
20. Kumar S. Engineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediation. Expert Opin. Drug Metab. Toxicol. 2010, 6:115-131.
21. Lafrance J.P., Miller D.R. Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury. Pharmacoepidemiol. Drug Saf. 2009, 18:923-931.
22. Laine L., Goldkind L., Curtis S.P., Connors L.G., Yanqiong Z., Cannon C.P. How common is diclofenac-associated liver injury? Analysis of 17, 289 arthritis patients in a long-term prospective clinical trial. Am. J. Gastroenterol. 2009, 104:356-362.
23. Lal N., Kumar J., Erdahl W.E., Pfeiffer D.R., Gadd M.E., Graff G., Yanni J.M. Differential effects of non-steroidal anti-inflammatory drugs on mitochondrial dysfunction during oxidative stress. Arch. Biochem. Biophys. 2009, 490:1-8.
24. Leite S., Martins N.M., Dorta D.J., Curti C., Uyemura S.A., dos Santos A.C. Mitochondrial uncoupling by the sulindac metabolite, sulindac sulfide. Basic Clin. Pharmacol. Toxicol. 2006, 99:294-299.
25. Lewis S.C., Langman M.J., Laporte J.R., Matthews J.N., Rawlins M.D., Wiholm B.E. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br. J. Clin. Pharmacol. 2002, 54:320-326.
26. Masubuchi Y., Saito H., Horie T. Structural requirements for the hepatotoxicity of nonsteroidal anti-inflammatory drugs in isolated rat hepatocytes. J. Pharmacol. Exp. Ther. 1998, 287:208-213.
27. Mima S., Ushijima H., Hwang H.J., Tsutsumi S., Makise M., Yamaguchi Y., Tomofusa T., Mizushima H., Mizushima T. Identification of the TPO1 gene in yeast, and its human orthologue TETRAN, which cause resistance to NSAIDs. FEBS Lett. 2007, 581:1457-1463.
28. Mitchell J.A., Warner T.D. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br. J. Pharmacol. 1999, 128:1121-1132.
29. Moreno-Sanchez R., Bravo C., Vasquez C., Ayala G., Silveira L.H., Martinez-Lavin M. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem. Pharmacol. 1999, 57:743-752.
30. Nakajima M., Inoue T., Shimada N., Tokudome S., Yamamoto T., Kuroiwa Y. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab. Dispos. 1998, 26:261-266.
31. Nozaki Y., Kusuhara H., Kondo T., Iwaki M., Shiroyanagi Y., Nakayama H., Horita S., Nakazawa H., Okano T., Sugiyama Y. Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J. Pharmacol. Exp. Ther. 2007, 322:1162-1170.
32. Obach R.S., Kalgutkar A.S., Soglia J.R., Zhao S.X. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem. Res. Toxicol. 2008, 21:1814-1822.
33. Patel V.A., Dunn M.J., Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J. Biol. Chem. 2002, 277:38915-38920.
34. Reid G., Wielinga P., Zelcer N., van der Heijden I., Kuil A., de Haas M., Wijnholds J., Borst P. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc. Natl. Acad. Sci. U S A 2003, 100:9244-9249.
35. Rodrigues A.D., Kukulka M.J., Roberts E.M., Ouellet D., Rodgers T.R. [O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab. Dispos. 1996, 24:126-136.
36. Roller A., Bahr O.R., Streffer J., Winter S., Heneka M., Deininger M., Meyermann R., Naumann U., Gulbins E., Weller M. Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. Biochem. Biophys. Res. Commun. 1999, 259:600-605.
37. Sawamura R., Okudaira N., Watanabe K., Murai T., Kobayashi Y., Tachibana M., Ohnuki T., Masuda K., Honma H., Kurihara A., Okazaki O. Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab. Dispos. 2010, 38:1857-1864.
38. Shen S.J., Marchick M.R., Davis M.R., Doss G.A., Pohl L.R. Metabolic activation of diclofenac by human cytochrome P450 3A4: Role of 5-hydroxydiclofenac. Chem. Res. Toxicol. 1999, 12:214-222.
39. Steinmetz L.M., Scharfe C., Deutschbauer A.M., Mokranjac D., Herman Z.S., Jones T., Chu A.M., Giaever G., Prokisch H., Oefner P.J., Davis R.W. Systematic screen for human disease genes in yeast. Nat. Genet. 2002, 31:400-404.
40. Takara K., Hayashi R., Kokufu M., Yamamoto K., Kitada N., Ohnishi N., Yokoyama T. Effects of nonsteroidal anti-inflammatory drugs on the expression and function of P-glycoprotein/MDR1 in Caco-2 cells. Drug Chem. Toxicol. 2009, 32:332-337.
41. Tatebe S., Sinicrope F.A., Kuo M.T. Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem. Biophys. Res. Commun. 2002, 290:1427-1433.
42. Thakur J.K., Arthanari H., Yang F., Pan S.J., Fan X., Breger J., Frueh D.P., Gulshan K., Li D.K., Mylonakis E., Struhl K., Moye-Rowley W.S., Cormack B.P., Wagner G., Naar A.M. A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 2008, 452:604-609.
43. van Leeuwen J.S., Orij R., Luttik M.A., Smits G.J., Vermeulen N.P., Vos J.C. Subunits Rip1p and Cox9p of the respiratory chain contribute to diclofenac-induced mitochondrial dysfunction. Microbiology 2011, 157:685-694.
44. van Leeuwen J.S., Vredenburg G., Dragovic S., Tjong T.F., Vos J.C., Vermeulen N.P. Metabolism related toxicity of diclofenac in yeast as model system. Toxicol. Lett. 2011, 200:162-168.
45. van Leeuwen J.S., Vermeulen N.P., Vos J.C. Involvement of the pleiotropic drug resistance response, protein kinase C signaling, and altered zinc homeostasis in resistance of saccharomyces cerevisiae to diclofenac. Appl. Environ. Microbiol. 2011, 77:5973-5980.
46. Yan Z., Li J., Huebert N., Caldwell G.W., Du Y., Zhong H. Detection of a novel reactive metabolite of diclofenac: evidence for CYP2C9-mediated bioactivation via arene oxides. Drug Metab. Dispos. 2005, 33:706-713.
47. Yang Z., Hollande F., Baldwin G.S. Blockade of long chain fatty acid oxidation by non-steroidal anti-inflammatory drugs may contribute to inhibition of proliferation of human colorectal carcinoma cell lines. Cancer Lett. 1998, 124:187-191.
48. Yasokawa D., Iwahashi H. Toxicogenomics using yeast DNA microarrays. J. Biosci. Bioeng. 2010, 110:511-522.
49. Yu L., Lopez A., Anaflous A., El Bali B., Hamal A., Ericson E., Heisler L.E., McQuibban A., Giaever G., Nislow C., Boone C., Brown G.W., Bellaoui M. Chemical-genetic profiling of imidazo[1,2-a]pyridines and -pyrimidines reveals target pathways conserved between yeast and human cells. PLoS Genet. 2008, 4:e1000284.
50. Zrieki A., Farinotti R., Buyse M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm. Res. 2008, 25:1991-2001.